No antiepileptic drug is completely safe to use in pregnancy as the risk of fetal abnormality is increased. Valproate should be avoided if possible because of the risk of major malformations. Ideally a plan for managing the woman's epilepsy during pregnancy should be prepared before conception. The occurrence of an unexpected pregnancy should not trigger sudden cessation or alteration of antiepileptic drug treatment without medical advice. The smallest effective dose of a drug with a low risk of teratogenicity should be used. Doses may need adjustment as the pharmacokinetics of some drugs change during pregnancy. Data are limited, but most antiepileptic drugs seem to have little effect on full-term breastfed babies.
Introduction
Uncontrolled epilepsy in a pregnant woman is a serious and potentially life-threatening condition for both mother and child. Most pregnant women with epilepsy will need to take at least one antiepileptic drug. The goal for all concerned is a healthy, seizure-free mother and an undamaged child. The following somewhat contradictory issues need to be considered concurrently.
• The optimum treatment of the mother's epilepsy requires that the most appropriate antiepileptic drug be used in effective doses throughout pregnancy. This requires knowledge of specific epileptic syndromes and also antiepileptic drug pharmacokinetics before, during and after pregnancy.
• Any adverse effect that the antiepileptic drug could have on the developing child needs to be avoided or minimised during pregnancy and lactation.
Fetal abnormality
Women with epilepsy taking antiepileptic drugs have a greater (2-3 times) risk than other women of having a baby with a fetal abnormality. Taking more than one antiepileptic drug carries a higher risk than monotherapy. Major malformations, such as congenital heart disease, neural tube defects, urogenital defects and cleft lips or palates, occur in about 3-7% of women with epilepsy who take antiepileptic drugs, although a substantially higher risk is attributed to high doses of valproate (greater than 1400 mg/day). When it is unavoidable, the lowest effective dose should be used. It should not exceed 1000 mg/day in divided doses.
Drug exposure and effects
The woman needs to be warned of the risk of seizures and she should avoid seizure triggers such as sleep deprivation.
While she is taking a reduced dose she may have to restrict her driving.
If the valproate dose has been reduced to a minimum during pregnancy in order to reduce teratogenesis, the prepartum effective dose may need to be re-established before the onset of labour. This is a time of increased seizure risk especially in patients with idiopathic generalised epilepsy who are very sensitive to sleep deprivation.
Breastfeeding is considered compatible with valproate therapy.
Valproate concentrations in breastfed babies are low.
Lamotrigine
The North American Pregnancy Register has reported that exposure to lamotrigine in the first trimester may cause an increased risk of oral clefts (a rate of 8.9 per 1000, as compared to 0.37 per 1000 in the reference population). 4 Significant doserelated teratogenesis with lamotrigine exceeding 200 mg/day has been reported. 5 Lamotrigine clearance increases steadily through to 32 weeks of pregnancy. Plasma concentrations of lamotrigine fall early in pregnancy so dose increases may be necessary to control seizures. A trough plasma lamotrigine concentration before pregnancy, at the onset of the second trimester of pregnancy and every two months during pregnancy may help to guide any necessary increase in lamotrigine dose. Postpartum, the lamotrigine concentration rises within a few days and prompt dose reduction may be required to prevent toxicity. 6 Lamotrigine is excreted in considerable amounts into breast milk. Early reports show that most full-term babies seem to have little problem with breastfeeding, but close monitoring for toxicity, especially in small or preterm babies, is advised. 
Carbamazepine

Levetiracetam
Levetiracetam has been used in few pregnancies. Its teratogenic risk is unknown.
There appears to be a substantial increase in clearance during pregnancy and an associated fall of blood concentrations. 7 
Conclusion
In women with epilepsy treated with antiepileptic drugs, there is a better than 90% chance that the child will be normal. The most specific therapeutic dilemma and the highest risk is in women who need to take valproate to control their epilepsy.
Most infants whose mothers are taking antiepileptic drugs can be successfully breastfed without complications. 
